Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC1616 | H-1152 dihydrochloride |
| Rho-kinase (ROCK) inhibitor that displays high selectivity over other protein kinases (IC50 values are 0.012, 0.180, 0.360, 0.745, 3.03, 5.68 and 28.3 μM for ROCKII, CAMKII, PKG, Aurora A, PKA, PKC and MLCK respectively). Inhibits sulprostone-induced contractions in guinea pig aorta (IC50 = 190 nM) and displays proerectile effects in rats. Glycyl derivative available. | |
| BCC1646 | INCB 3284 dimesylate |
| Potent, selective hCCR2 antagonist. Exhibits potent antagonism against monocyte chemoattractant molecule binding to hCCR2 and chemotaxis activity (IC50 values are 3.7 and 4.7 nM respectively). Also displays weak hERG activity; inhibits the hERG potassium current (IC50 = 84μM). Orally bioavailable. | |
| BCC1659 | IRAK-1-4 Inhibitor I |
| IRAK4 and IRAK1 inhibitor (IC50 values are 0.2 and 0.3 μM, respectively). | |
| BCC1665 | IWP-2 |
| Inhibitor of Wnt processing and secretion. Inactivates PORCN, a membrane-bound O-acyltransferase (MBOAT), and selectively inhibits palmitoylation of Wnt. Blocks Wnt-dependent phosphorylation of Lrp6 receptor and Dvl2, and β-catenin accumulation. Suppresses self-renewal in R1 embryonic stem cells. | |
| BCC1683 | KN-93 |
| Potent, cell permeable inhibitor of CaM kinase II (IC50 = 0.37 μM). Also a direct extracellular open channel blocker of voltage-gated potassium channels (IC50 = 307 nM for KV1.5) and abolishes IKr in ventricular myocytes (IC50 = 102.6 nM) independently of CaM kinase II inhibition. Water soluble form also available. | |
| BCC1685 | KU14R |
| Antagonist of the atypical imidazoline binding site (putative I3 receptor) of pancreatic β-cells. Selectively blocks efaroxan-induced insulin secretion in vitro and in vivo. | |
| BCC1689 | Lck Inhibitor |
| Potent inhibitor of lymphocyte specific kinase (Lck). IC50 values are 0.007, 0.021, 0.042 and 0.20 μM for Lck, Lyn, Src and Syk kinases respectively. Displays >1000-fold selectivity for Lck over MAPK, CDK and RSK family representatives. Inhibits T cell proliferation in vitro and inhibits arthritis in two in vivo models. Orally active. | |
| BCC1715 | LY 303511 |
| Negative control compound with respect to LY 294002 PI 3-kinase inhibitory activity. Blocks voltage-gated potassium (Kv) channels (IC50 = 64.6 μM) and inhibits IL-1β-stimulated NF-κB activation, attenuating MCP-1 expression. Antiproliferative. Also inhibits the BET bromodomain proteins BRD2, BRD3 and BRD4. | |
